{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:05Z","timestamp":1792112285652,"version":"4.4.0"},"reference-count":243,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Antibody-drug conjugates (ADCs), often referred to as \u201cintelligent biological missiles,\u201d have garnered significant attention in the rapidly evolving landscape of cancer therapy. ADCs represent a sophisticated approach by integrating monoclonal antibodies (mAbs), which are particular targeting tumor antigens, with cytotoxic payloads, which deliver lethal effects. Compared with the combination of chemotherapy and mAbs, ADCs precisely deliver highly potent cytotoxins directly to tumor cells while minimizing damage to healthy tissues. However, limitations such as significant adverse effects, suboptimal therapeutic efficacy, and drug resistance require carefully evaluation and further optimization. Further studies are necessary to explore the next-generation of ADCs, such as the combination of ADCs with other anti-tumor strategies, bispecific ADCs, dual-payload ADCs and radionuclide drug conjugates (RDCs). This review provides a comprehensive overview of recent developments in oncology treatment, focusing on the historical evolution, structural design, clinical advancements, and mechanisms of action of approved ADCs. Each structural element, including the target antigen, mAb, linker system, and cytotoxic payload, as well as advancements in payload conjugation technology, plays a critical role in the development of ADCs. Through ongoing refinement and innovation, it is anticipated that next-generation ADCs with enhanced therapeutic benefits for patient populations can be realized.<\/jats:p>","DOI":"10.3389\/fcell.2025.1669592","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T05:42:49Z","timestamp":1759902169000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs"],"prefix":"10.3389","volume":"13","author":[{"given":"Dan","family":"Wu","sequence":"first","affiliation":[{"name":"Cancer Center, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"School of Pharmacy, Southwest Medical University","place":["Luzhou, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Cancer Center, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runjia","family":"He","sequence":"additional","affiliation":[{"name":"Acupuncture and Tuina School, Chengdu University of Traditional Chinese Medicine","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[{"name":"Cancer Center, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shui","sequence":"additional","affiliation":[{"name":"Cancer Center, West China Second University Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1248\/cpb.c19-00853","article-title":"Antibody-drug conjugate payloads; study of Auristatin derivatives","volume":"68","author":"Akaiwa","year":"2020","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1002\/cncr.24373","article-title":"Outcomes and quality of care in acute myeloid leukemia over 40 years","volume":"115","author":"Alibhai","year":"2009","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: the single-arm phase II PICCOLO trial","volume":"36","author":"Alvarez Secord","year":"2025","journal-title":"Ann. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/jco.2015.64.0060","article-title":"Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial","volume":"34","author":"Amadori","year":"2016","journal-title":"J. Clin. Oncol. Official J. Am. Soc. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1158\/1078-0432.CCR-14-0012","article-title":"FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer","volume":"20","author":"Amiri-Kordestani","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e202102592","DOI":"10.1002\/cssc.202102592","article-title":"Galactose oxidase enables modular assembly of conjugates from native antibodies with high drug-to-antibody ratios","volume":"15","author":"Angelastro","year":"2022","journal-title":"ChemSusChem"},{"key":"B9","doi-asserted-by":"publisher","first-page":"25914","DOI":"10.1002\/anie.202109835","article-title":"Diazaborines are a versatile platform to develop ROS-responsive antibody drug conjugates","volume":"60","author":"Ant\u00f3nio","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1021\/acs.bioconjchem.4c00348","article-title":"Linker and conjugation site synergy in antibody-drug conjugates: impacts on biological activity","volume":"35","author":"Aoyama","year":"2024","journal-title":"Bioconjug Chem."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/1535-7163.MCT-23-0298","article-title":"An antibody-drug conjugate directed to tissue factor shows preclinical antitumor activity in head and neck cancer as a single agent and in combination with chemoradiotherapy","volume":"23","author":"Bakema","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40265-013-0050-2","article-title":"Trastuzumab emtansine: first global approval","volume":"73","author":"Ballantyne","year":"2013","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"","journal-title":"Ann. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"","journal-title":"Ann. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"","journal-title":"N. Engl. J. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab deruxtecan in advanced or metastatic HR+\/HER2-and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study","volume":"42","author":"Bardia","year":"","journal-title":"J. Clin. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2217\/fon-2023-0188","article-title":"TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+\/HER2-breast cancer","volume":"20","author":"Bardia","year":"","journal-title":"Future Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/Metastatic hormone receptor-positive human epidermal growth factor receptor 2-Negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/jco.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013Negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/c8cs00676h","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1039\/d1cc00957e","article-title":"A dual-enzyme cleavable linker for antibody-drug conjugates","volume":"57","author":"Bargh","year":"2021","journal-title":"Chem. Commun. (Camb)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/jco-24-02242","article-title":"Brentuximab vedotin combination for relapsed diffuse large B-Cell lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"25416","DOI":"10.1021\/jacs.4c07754","article-title":"Tunable and photoactivatable mimics of calicheamicin \u03b31 for DNA cleavage","volume":"146","author":"Ben-Zvi","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA approval summary: Enfortumab Vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.semcancer.2020.02.013","article-title":"Small-molecule drug repurposing to target DNA damage repair and response pathways","volume":"68","author":"Brinkman","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"B28","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/1538-7445.Am2017-5588","article-title":"Abstract 5588: Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo","volume":"77","author":"Cao","year":"2017","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting Nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1158\/1078-0432.CCR-20-2275","article-title":"FDA approval summary: Enfortumab vedotin for locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Chang","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun. (Lond)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-025-01698-y","article-title":"The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China: a comprehensive nationwide cohort analysis","volume":"18","author":"Chen","year":"","journal-title":"J. Hematol. and Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"bbaf228","DOI":"10.1093\/bib\/bbaf228","article-title":"ADCNet: a unified framework for predicting the activity of antibody-drug conjugates","volume":"26","author":"Chen","year":"","journal-title":"Brief. Bioinform"},{"key":"B39","doi-asserted-by":"publisher","first-page":"951589","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3322\/caac.21634","article-title":"Evolving standards of care and new challenges in the management of HER2-positive breast cancer","volume":"70","author":"Choong","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.jtho.2021.06.022","article-title":"A phase 1 study evaluating rovalpituzumab tesirine in frontline treatment of patients with extensive-stage SCLC","volume":"16","author":"Christine","year":"2021","journal-title":"J. Thorac. Oncol. official Publ. Int. Assoc. Study Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1002\/hed.26885","article-title":"Phase 1\/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma","volume":"43","author":"Cognetti","year":"2021","journal-title":"Head. Neck"},{"key":"B43","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.2174\/1871520622666220421095240","article-title":"Tisotumab vedotin: the first FDA-approved antibody-drug conjugate for cervical cancer","volume":"22","author":"De","year":"2022","journal-title":"Anticancer Agents Med. Chem."},{"key":"B48","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1021\/acs.bioconjchem.2c00611","article-title":"Generation of DAR1 antibody-drug conjugates for ultrapotent payloads using tailored GlycoConnect technology","volume":"34","author":"de Bever","year":"2023","journal-title":"Bioconjug Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"de Bono","year":"2019","journal-title":"Lancet Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/1535-7163.MCT-14-0798","article-title":"High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates","volume":"14","author":"de Goeij","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab vedotin: first global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMra1204479","article-title":"Two hundred years of cancer research","volume":"366","author":"DeVita","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","article-title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","volume":"18","author":"Di\u00e9ras","year":"2017","journal-title":"Lancet Oncol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-Positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"188308","DOI":"10.1016\/j.bbcan.2019.07.003","article-title":"Cell death in photodynamic therapy: from oxidative stress to anti-tumor immunity","volume":"1872","author":"Donohoe","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"TPS8593","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS8593","article-title":"A phase 1\/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with mesenchymal epithelial transition factor (MET)-Overexpressing NSCLC","volume":"40","author":"Drilon","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/19420862.2018.1503904","article-title":"T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways","volume":"10","author":"Endo","year":"2018","journal-title":"MAbs"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMra2406376","article-title":"Hairy-cell leukemia","volume":"391","author":"Falini","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"9114","DOI":"10.1200\/JCO.2023.41.16_suppl.9114","article-title":"SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: efficacy and safety data from a phase 2 study","volume":"41","author":"Fang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1056\/NEJMoa0904544","article-title":"Anthracycline dose intensification in acute myeloid leukemia","volume":"361","author":"Fernandez","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1182\/blood-2003-01-0039","article-title":"cAC10-vcMMAE, an anti-CD30-monomethyl Auristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Francisco","year":"2003","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/hep.30326","article-title":"Glypican-3-Specific antibody drug conjugates targeting hepatocellu lar carcinoma","volume":"70","author":"Fu","year":"2019","journal-title":"Hepatology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B65","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bph.13697","article-title":"Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells","volume":"174","author":"Fuh","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1002\/cam4.3815","article-title":"Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors","volume":"10","author":"Fujiwara","year":"2021","journal-title":"Cancer Med."},{"key":"B67","doi-asserted-by":"publisher","first-page":"LBA500","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA500","article-title":"De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): a multicentre, open-label, randomised, phase 3 trial","volume":"43","author":"Gao","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1158\/1538-7445.Am2015-2469","article-title":"Abstract 2469: Brentuximab vedotin-mediated immunogenic cell death","volume":"75","author":"Gardai","year":"2015","journal-title":"Cancer Res."},{"key":"B69","doi-asserted-by":"publisher","first-page":"P9","DOI":"10.1164\/rccm.2055P9","article-title":"Treatment of advanced-stage non-small cell lung cancer","volume":"205","author":"Gesthalter","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.3390\/ijms20082041","article-title":"Twist and turn-topoisomerase functions in mitochondrial DNA maintenance","volume":"20","author":"Goffart","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B72","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4155\/tde.10.98","article-title":"Antibody-drug conjugates: using monoclonal antibodies for delivery of cytotoxic payloads to cancer cells","volume":"2","author":"Goldmacher","year":"2011","journal-title":"Ther. Deliv."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e98354","DOI":"10.15252\/embj.201798354","article-title":"Photodynamic therapy with redaporfin targets the endoplasmic reticulum and golgi apparatus","volume":"37","author":"Gomes-da-Silva","year":"2018","journal-title":"EMBO J."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1841393","DOI":"10.1080\/2162402X.2020.1841393","article-title":"Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death","volume":"9","author":"Gomes-da-Silva","year":"2020","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.blre.2014.06.003","article-title":"Hairy cell leukemia: update on molecular profiling and therapeutic advances","volume":"28","author":"Grever","year":"2014","journal-title":"Blood Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"B77","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(25)00158-5","article-title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","volume":"26","author":"Gupta","year":"2025","journal-title":"Lancet Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"102286","DOI":"10.1016\/j.ctrv.2021.102286","article-title":"Targeting HER2 heterogeneity in breast cancer","volume":"100","author":"Hamilton","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1002\/cmdc.202000497","article-title":"Rational design of azastatin as a potential ADC payload with reduced bystander killing","volume":"15","author":"Hartmann","year":"2020","journal-title":"ChemMedChem"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jamaoncol.2021.1932","article-title":"Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-Positive breast cancer: a phase 2 randomized clinical trial","volume":"7","author":"Hatschek","year":"2021","journal-title":"JAMA Oncol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin-driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab soravtansine: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395127","article-title":"Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs)","volume":"7","author":"Hoffmann","year":"2018","journal-title":"OncoImmunology"},{"key":"B84","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3390\/cells8040362","article-title":"The Cytoskeleton-A complex interacting meshwork","volume":"8","author":"Hohmann","year":"2019","journal-title":"Cells"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2490078","DOI":"10.1080\/19420862.2025.2490078","article-title":"Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate","volume":"17","author":"Hwai Wen","year":"2025","journal-title":"mAbs"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3390\/cancers13071663","article-title":"Immune-checkpoint inhibitors in platinum-resistant ovarian cancer","volume":"13","author":"Indini","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41580-020-0214-3","article-title":"The tubulin code and its role in controlling microtubule properties and functions","volume":"21","author":"Janke","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"101086","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist Updat"},{"key":"B89","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","article-title":"Emerging new therapeutic antibody derivatives for cancer treatment","volume":"7","author":"Jin","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Jonathan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/s1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Jonathan","year":"2021","journal-title":"Lancet. Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10549-010-1090-x","article-title":"Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer","volume":"128","author":"Junttila","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jtho.2021.02.022","article-title":"A phase 1-2 study of rovalpituzumab tesirine in combination with nivolumab plus or minus ipilimumab in patients with previously treated extensive-stage SCLC","volume":"16","author":"Jyoti","year":"2021","journal-title":"J. Thorac. Oncol. official Publ. Int. Assoc. Study Lung Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-1457","article-title":"Probody therapeutics: an emerging class of therapies designed to enhance On-Target effects with reduced off-tumor toxicity for use in immuno-oncology","volume":"26","author":"Karen","year":"2019","journal-title":"Clin. cancer Res. official J. Am. Assoc. Cancer Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1021\/acs.bioconjchem.3c00366","article-title":"Antibody-proteolysis targeting chimera conjugate enables selective degradation of receptor-interacting Serine\/threonine-protein kinase 2 in HER2+ cell lines","volume":"34","author":"Karina","year":"2023","journal-title":"Bioconjug Chem."},{"key":"B97","doi-asserted-by":"publisher","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40265-020-01281-4","article-title":"Trastuzumab deruxtecan: first approval","volume":"80","author":"Keam","year":"2020","journal-title":"Drugs"},{"key":"B99","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s40259-018-0302-5","article-title":"Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody-drug conjugates","volume":"32","author":"Khera","year":"2018","journal-title":"BioDrugs"},{"key":"B100","doi-asserted-by":"publisher","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B101","doi-asserted-by":"publisher","first-page":"S450","DOI":"10.1016\/j.annonc.2021.08.491","article-title":"209P interim results of a phase I\/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors","volume":"32","author":"Klempner","year":"2021","journal-title":"Ann. Oncol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"K\u00f6hler","year":"1975","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13045-025-01686-2","article-title":"Mirvetuximab soravtansine: current and future applications","volume":"18","author":"Kong","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"6949","DOI":"10.1021\/jm500766w","article-title":"Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer","volume":"57","author":"Lambert","year":"2014","journal-title":"J. Med. Chem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3390\/cancers12020303","article-title":"CD22 expression in B-Cell acute lymphoblastic leukemia: biological significance and implications for inotuzumab therapy in adults","volume":"12","author":"Lanza","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B109","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1021\/ar00008a003","article-title":"Calicheamicins: discovery, structure, chemistry, and interaction with DNA","volume":"24","author":"Lee","year":"1991","journal-title":"Accounts Chem. Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s42003-020-01591-z","article-title":"CD79a promotes CNS-Infiltration and leukemia engraftment in pediatric B-cell precursor acute lymphoblastic leukemia","volume":"4","author":"Lenk","year":"2021","journal-title":"Commun. Biol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1200\/JCO.2011.35.4928","article-title":"MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib","volume":"29","author":"Lennerz","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"774577","DOI":"10.3389\/fonc.2021.774577","article-title":"In real life, low-level HER2 expression may be associated with better outcome in HER2-Negative breast cancer: a study of the national cancer center, China","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40364-022-00416-x","article-title":"HER2-targeted advanced metastatic gastric\/gastroesophageal junction adenocarcinoma: treatment landscape and future perspectives","volume":"10","author":"Li","year":"2022","journal-title":"Biomark. Res."},{"key":"B114","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"","journal-title":"Signal Transduct. Target Ther."},{"key":"B115","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/cncr.35349","article-title":"The safety of trastuzumab deruxtecan (DS-8201) with a focus on interstitial lung disease And\/Or pneumonitis: a systematic review and single-arm meta-analysis","volume":"130","author":"Li","year":"","journal-title":"Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"","journal-title":"Lancet Oncol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40164-025-00632-9","article-title":"Antibody-drug conjugates in breast cancer: current evidence and future directions","volume":"14","author":"Li","year":"","journal-title":"Exp. Hematol. Oncol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.annonc.2025.02.011","article-title":"Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase II trial","volume":"36","author":"Li","year":"","journal-title":"Ann. Oncol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.v98.4.988","article-title":"Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin","volume":"98","author":"Linenberger","year":"2001","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3390\/antib9040064","article-title":"Fc-Engineering for modulated effector functions-improving antibodies for cancer treatment","volume":"9","author":"Liu","year":"2020","journal-title":"Fc-Engineering Modul. Eff. Functions-Improving Antibodies Cancer Treat. Antibodies (Basel)"},{"key":"B121","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3892\/ijo.2021.5273","article-title":"Role of Nectin\u20114 protein in cancer (review)","volume":"59","author":"Liu","year":"2021","journal-title":"Int. J. Oncol."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03792-7","article-title":"A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial","author":"Liu","year":"2025","journal-title":"Nat. Med"},{"key":"B123","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"B124","doi-asserted-by":"crossref","DOI":"10.3390\/antib7010010","article-title":"Factors affecting the pharmacology of antibody-drug conjugates","volume-title":"Antibodies (Basel)","author":"Lucas","year":"2018"},{"key":"B125","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/cancers11010010","article-title":"Therapy landscape in patients with metastatic HER2-Positive breast cancer: data from the PRAEGNANT real-world breast cancer registry","volume":"11","author":"Lux","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B126","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1023\/a:1023768811842","article-title":"c-Met: structure, functions and potential for therapeutic inhibition","volume":"22","author":"Ma","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","article-title":"Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer","volume":"43","author":"Ma","year":"2025","journal-title":"Cancer Cell"},{"key":"B128","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(21)00191-1","article-title":"The era of CD19-directed therapy in diffuse large B-cell lymphoma","volume":"22","author":"Maddocks","year":"2021","journal-title":"Lancet Oncol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B130","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-Containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"B131","doi-asserted-by":"publisher","first-page":"18230","DOI":"10.1021\/jacs.5c05198","article-title":"Small organic carbonic anhydrase IX ligands from DNA-Encoded chemical libraries for tumor-targeted delivery of radionuclides","volume":"147","author":"Marco","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s40265-020-01404-x","article-title":"Belantamab Mafodotin: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1007\/s40265-021-01633-8","article-title":"Tisotumab vedotin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"B134","doi-asserted-by":"publisher","first-page":"103501","DOI":"10.1016\/j.ebiom.2021.103501","article-title":"Near infrared photoimmunotherapy for cancers: a translational perspective","volume":"70","author":"Maruoka","year":"2021","journal-title":"EBioMedicine"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","article-title":"Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia group B","volume":"331","author":"Mayer","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"B137","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41408-024-01135-2","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed\/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial","volume":"14","author":"McCurdy","year":"2024","journal-title":"Blood Cancer J."},{"key":"B138","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/jco.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-Expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1200\/JCO.2025.43.5_suppl.663","article-title":"Datopotamab deruxtecan (Dato-DXd) in locally advanced\/metastatic urothelial cancer: updated results from the phase 1 TROPIONPanTumor01 study","volume":"43","author":"Meric-Bernstam","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1200\/JCO.2020.38.15_suppl.3110","article-title":"SBT6050, a HER2-directed TLR8 therapeutic, as a systemically administered, tumor-targeted human myeloid cell agonist","volume":"38","author":"Metz","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1080\/00498254.2024.2351044","article-title":"Translational PK\/PD framework for antibody-drug conjugates to inform drug discovery and development","volume":"54","author":"Michael","year":"2024","journal-title":"Xenobiotica"},{"key":"B142","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"B143","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-Positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"B145","doi-asserted-by":"publisher","first-page":"S1169","DOI":"10.1016\/j.jtho.2021.08.633","article-title":"P60.12 prevalence of c-Met overexpression (c-Met+) and impact of prior lines of treatment on c-Met protein expression in NSCLC","volume":"16","author":"Motwani","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/d41573-021-00082-y","article-title":"FDA approves ADC therapeutics' loncastuximab tesirine, ushering in a new cytotoxic payload","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B147","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"M\u00fcller","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"B148","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","article-title":"Progress in systemic therapy for advanced-stage urothelial carcinoma","volume":"21","author":"Nadal","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"705294","DOI":"10.3389\/fonc.2021.705294","article-title":"Elucidation of novel molecular targets for therapeutic strategies in urothelial carcinoma: a literature review","volume":"11","author":"Nelson","year":"2021","journal-title":"Front. Oncol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41571-024-00913-y","article-title":"Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins","volume":"21","author":"Neri","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"149","DOI":"10.37349\/etat.2022.00077","article-title":"Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?","volume":"3","author":"Nerone","year":"2022","journal-title":"Explor Target Antitumor Ther."},{"key":"B152","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B153","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.tips.2009.02.005","article-title":"Siglecs as targets for therapy in immune-cell-mediated disease","volume":"30","author":"O'Reilly","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"B154","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"B155","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"B156","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1158\/1078-0432.CCR-09-2069","article-title":"Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate","volume":"16","author":"Okeley","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"S7-S19","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B158","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1158\/1538-7445.Am2023-2700","article-title":"Abstract 2700: ORM-6151: a first-in-class CD33-antibody enabled GSPT1 degrader for AML","volume":"83","author":"Palacino","year":"2023","journal-title":"Cancer Res."},{"key":"B159","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun. (Lond)"},{"key":"B161","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2015.48","article-title":"Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes","volume":"29","author":"Pfeifer","year":"2015","journal-title":"Leukemia"},{"key":"B163","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2007-01-066704","article-title":"Antibody-drug conjugates targeted to CD79 for the treatment of Non-Hodgkin lymphoma","volume":"110","author":"Polson","year":"2007","journal-title":"Blood"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B165","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"B167","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1200\/JCO.2025.43.16_suppl.2060","article-title":"Efficacy and safety of depatuxizumab mafodotin (ABT-414) in EGFR-Amplified glioblastoma: a systematic review and Bayesian network meta-analysis","volume":"43","author":"Promi","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2008-06-164863","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte","year":"2009","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","first-page":"PO3","DOI":"10.1158\/1538-7445.Sabcs23-po3-04-05","article-title":"Abstract PO3-04-05: efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing, metastatic breast cancer: a single-arm phase II study","volume":"84","author":"Qu","year":"2024","journal-title":"Cancer Res."},{"key":"B171","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"B172","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10585-021-10080-4","article-title":"Breast cancer liver metastasis: current and future treatment approaches","volume":"38","author":"Rashid","year":"2021","journal-title":"Clin. and Exp. metastasis"},{"key":"B173","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Rebecca","year":"2025","journal-title":"CA a cancer J. Clin."},{"key":"B174","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.1021\/bi901655t","article-title":"Solution structure of a covalently bound pyrrolo[2,1-c] [1,4]benzodiazepine-benzimidazole hybrid to a 10mer DNA duplex","volume":"48","author":"Rettig","year":"2009","journal-title":"Biochemistry"},{"key":"B175","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B176","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res."},{"key":"B177","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett."},{"key":"B178","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/Programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B179","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"B180","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","article-title":"In vivo drug-linker stability of an anti-CD30 dipeptide-linked Auristatin immunoconjugate","volume":"11","author":"Sanderson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"B181","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1200\/JCO.23.02767","article-title":"Efficacy and safety of sacituzumab govitecan in patients with advanced solid tumors (TROPiCS-03): analysis in patients with advanced endometrial cancer","volume":"42","author":"Santin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B183","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1021\/acscentsci.8b00565","article-title":"Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy","volume":"4","author":"Sato","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"B184","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B185","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-Cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B186","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/jco.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/ijc.33002","article-title":"B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: clinical experience and future perspectives","volume":"147","author":"Sellner","year":"2020","journal-title":"Int. J. Cancer"},{"key":"B188","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"B189","doi-asserted-by":"publisher","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","article-title":"Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-Positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial","volume":"6","author":"Shao","year":"2020","journal-title":"JAMA Oncol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","article-title":"Open-label, multicenter, phase II study of RC48-ADC, a HER2-Targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma","volume":"27","author":"Sheng","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B191","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/10717544.2022.2069883","article-title":"Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy","volume":"29","author":"Shi","year":"2022","journal-title":"Drug Deliv."},{"key":"B192","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12935-023-02991-x","article-title":"ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors","volume":"23","author":"Shin","year":"2023","journal-title":"Cancer Cell Int."},{"key":"B193","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","article-title":"Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions","volume":"17","author":"Short","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B194","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41591-021-01326-5","article-title":"Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells","volume":"27","author":"Singh","year":"2021","journal-title":"Nat. Med."},{"key":"B195","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"key":"B196","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"key":"B197","doi-asserted-by":"publisher","first-page":"3681","DOI":"10.1182\/blood.v96.12.3681","article-title":"CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B199","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical hodgkin lymphoma: 3-Year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"B200","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.chembiol.2013.01.010","article-title":"Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates","volume":"20","author":"Strop","year":"2013","journal-title":"Chem. Biol."},{"key":"B201","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","article-title":"Antibody\u2013drug conjugates: recent advances in linker chemistry","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"B202","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1158\/1535-7163.MCT-17-0403","article-title":"Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine (T-DM1)","volume":"17","author":"Sung","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"B203","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40265-020-01337-5","article-title":"Sacituzumab govitecan: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1002\/ijc.30870","article-title":"DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance","volume":"141","author":"Takegawa","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B205","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(19)30097-X","article-title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study","volume":"20","author":"Tamura","year":"2019","journal-title":"Lancet Oncol."},{"key":"B206","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B207","doi-asserted-by":"publisher","first-page":"LBA1008","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA1008","article-title":"Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2\u2013positive (HER2+) advanced\/metastatic breast cancer (a\/mBC): interim results from DESTINY-Breast09","volume":"43","author":"Tolaney","year":"","journal-title":"J. Clin. Oncol."},{"key":"B208","doi-asserted-by":"publisher","first-page":"LBA109","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109","article-title":"Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1\u2013positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04\/KEYNOTE-D19 study","volume":"43","author":"Tolaney","year":"","journal-title":"J. Clin. Oncol."},{"key":"B209","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"B210","doi-asserted-by":"publisher","first-page":"23717","DOI":"10.1021\/jacs.4c04567","article-title":"Use of a cyclic \u03b1-Alkylidene-\u03b2-Diketone as a cleavable linker strategy for antibody-drug conjugates","volume":"146","author":"Tong","year":"2024","journal-title":"J. Am. Chem. Soc."},{"key":"B211","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJMe2406799","article-title":"A belantamab mafodotin revival in multiple myeloma therapy","volume":"391","author":"Trudel","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B212","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2016","journal-title":"Protein and Cell"},{"key":"B213","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1158\/1078-0432.CCR-14-2093","article-title":"Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)","volume":"21","author":"Uppal","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"B214","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/d41573-019-00121-9","article-title":"FDA new drug approvals in Q2 2019","volume":"18","author":"Urquhart","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B215","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 study","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab vedotin as Second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B217","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B218","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B219","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: a biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"B220","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1158\/1078-0432.CCR-16-1568","article-title":"ABBV-399, a c-Met antibody-drug conjugate that targets both MET-amplified and c-Met-Overexpressing tumors, irrespective of MET pathway dependence","volume":"23","author":"Wang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B221","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s00262-022-03267-5","article-title":"Characterization of anti-CD79b\/CD3 bispecific antibody, a potential therapy for B cell malignancies","volume":"72","author":"Wang","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"B222","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1021\/acs.jmedchem.7b01430","article-title":"Discovery of peptidomimetic antibody-drug conjugate linkers with enhanced protease specificity","volume":"61","author":"Wei","year":"2018","journal-title":"J. Med. Chem."},{"key":"B223","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1021\/jm051199z","article-title":"Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates","volume":"49","author":"Wells","year":"2006","journal-title":"J. Med. Chem."},{"key":"B224","doi-asserted-by":"publisher","first-page":"116709","DOI":"10.1016\/j.ejmech.2024.116709","article-title":"Antibody-drug conjugates for targeted cancer therapy: recent advances in potential payloads","volume":"276","author":"Xi","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"B225","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/ijc.34424","article-title":"A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B226","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1200\/JCO.2024.42.16_suppl.104","article-title":"Sacituzumab tirumotecan (SKB264\/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): results from the phase III OptiTROP-Breast01 study","volume":"42","author":"Xu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B227","doi-asserted-by":"publisher","first-page":"4702","DOI":"10.1158\/1538-7445.Am2024-4702","article-title":"Abstract 4702: medilink\u2019s TMALIN ADC linker technology: tumor microenvironment specific extracellular and intracellular double cleavage mechanism for better efficacy and expanded target space","volume":"84","author":"Xue","year":"2024","journal-title":"Cancer Res."},{"key":"B228","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s12282-020-01153-5","article-title":"Development and biological assessment of MMAE-Trastuzumab antibody-drug conjugates (ADCs)","volume":"28","author":"Yaghoubi","year":"2021","journal-title":"Breast Cancer"},{"key":"B229","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/jco.23.02626","article-title":"Trastuzumab deruxtecan in advanced solid tumors with human epidermal growth factor receptor 2 amplification identified by plasma cell-free DNA testing: a multicenter, single-arm, phase II basket trial","volume":"42","author":"Yagisawa","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B230","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2025.43.16_suppl.3001","article-title":"Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with driver genomic alterations (GA) outside of classic EGFR mutations","volume":"43","author":"Yang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B231","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10549-015-3503-3","article-title":"A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity","volume":"153","author":"Yao","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"B232","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1200\/JCO.23.02044","article-title":"Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-Directed antibody-drug conjugate, in human epidermal growth factor receptor 2-Expressing or mutated advanced solid tumors: a global phase I trial","volume":"42","author":"Yao","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B233","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1200\/JCO.2025.43.5_suppl.796","article-title":"Efficacy and safety of sacituzumab Tirumotecan monotherapy in patients with advanced urothelial carcinoma who progressed on or after prior anti-cancer therapies: report from the phase 1\/2 MK-2870-001 study","volume":"43","author":"Ye","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"B234","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat. Med."},{"key":"B235","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory hodgkin's lymphoma","volume":"30","author":"Younes","year":"","journal-title":"J. Clin. Oncol."},{"key":"B236","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/jco.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory hodgkin's lymphoma","volume":"30","author":"Younes","year":"","journal-title":"J. Clin. Oncol."},{"key":"B237","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/ajh.27341","article-title":"Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed\/refractory B-cell Non-Hodgkin lymphoma","volume":"99","author":"Yuen","year":"2024","journal-title":"Am. J. Hematol."},{"key":"B238","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"B239","doi-asserted-by":"publisher","first-page":"LB031","DOI":"10.1158\/1538-7445.Am2023-lb031","article-title":"Abstract LB031: SHR-A1811, a novel anti-HER2 ADC with superior bystander effect, optimal DAR and favorable safety profiles","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"key":"B240","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.3892\/etm.2018.6723","article-title":"Expression of tissue factor in human cervical carcinoma tissue","volume":"16","author":"Zhao","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"B241","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-024-01595-w","article-title":"Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting","volume":"17","author":"Zhou","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"B242","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.annonc.2024.12.002","article-title":"Disitamab vedotin plus toripalimab in patients with locally advanced or metastatic urothelial carcinoma (RC48-C014): a phase Ib\/II dose-escalation and dose-expansion study","volume":"36","author":"Zhou","year":"2025","journal-title":"Ann. Oncol."},{"key":"B243","doi-asserted-by":"publisher","first-page":"188549","DOI":"10.1016\/j.bbcan.2021.188549","article-title":"HER2-targeted therapies in gastric cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"}],"updated-by":[{"DOI":"10.3389\/fcell.2026.1860706","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000}}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1669592\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T14:05:44Z","timestamp":1779717944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1669592\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":243,"alternative-id":["10.3389\/fcell.2025.1669592"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1669592","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"1669592"}}